World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
35519
World Ranking
10798
National Ranking
5557

Naval Daver publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Naval Daver sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,370 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Naval Daver D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Naval Daver sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Naval Daver is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the field of Medicine, with significant contributions in subfields including Hematology, Molecular Biology, Genetics, Oncology, and Public Health, Environmental and Occupational Health.

The scientist's work covers a range of topics focused heavily on leukemia and related hematologic conditions. Main topics of their research include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Histone Deacetylase Inhibitors Research
  • Protein Degradation and Inhibitors

Naval Daver has co-authored extensively with several prominent collaborators. Frequent co-authors include:

  • Tapan M. Kadia
  • Courtney D. DiNardo
  • Farhad Ravandi
  • Hagop M. Kantarjian
  • Guillermo Garcia-Manero

The scientist's publications appear in well-known medical and oncology journals. Frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • American Journal of Hematology
  • Journal of Clinical Oncology
  • Cancer

Naval Daver's recent papers illustrate a focus on acute myeloid leukemia and therapeutic advancements. Selected recent publications include:

  • Acute myeloid leukemia: current progress and future directions (2021), Blood Cancer Journal
  • MDM2 inhibition: an important step forward in cancer therapy (2020), Leukemia
  • Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials (2023), Nature Medicine
  • Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia (2021), Journal of Clinical Oncology
  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial (2020), The Lancet Haematology

Best Publications

  • Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    Sattva S. Neelapu;Sudhakar Tummala;Partow Kebriaei;William Wierda

  • An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

    Jennifer R. Molina;Yuting Sun;Marina Protopopova;Sonal Gera

  • Targeting FLT3 mutations in AML: review of current knowledge and evidence.

    Naval Daver;Richard F. Schlenk;Nigel H. Russell;Mark J. Levis

  • Acute myeloid leukemia: current progress and future directions.

    Hagop Kantarjian;Tapan Kadia;Courtney DiNardo;Naval Daver

  • Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

    Naval Daver;Guillermo Garcia-Manero;Sreyashi Basu;Prajwal C Boddu

  • Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

    Courtney D. DiNardo;Caitlin R. Rausch;Christopher Benton;Tapan Kadia

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

  • Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

    Jean Pierre J Issa;Jean Pierre J Issa;Gail Roboz;David Rizzieri;Elias Joseph Jabbour

  • Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

    Koji Sasaki;Koji Sasaki;Sara S Strom;Susan O'Brien;Elias Jabbour

  • Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study

    Elias Jabbour;Hagop Kantarjian;Farhad Ravandi;Deborah Thomas

  • MDM2 inhibition: an important step forward in cancer therapy

    Marina Konopleva;Giovanni Martinelli;Naval Daver;Cristina Papayannidis

  • Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab

    Yasmin Abaza;Hagop M. Kantarjian;Guillermo Garcia-Manero;Elihu Estey

  • The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

    Patrick Williams;Sreyashi Basu;Guillermo Garcia-Manero;Christopher S. Hourigan

  • Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

    Nicholas J. Short;Marina Konopleva;Tapan M. Kadia;Gautam Borthakur

  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

    Courtney D DiNardo;Abhishek Maiti;Caitlin R Rausch;Naveen Pemmaraju

  • Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

    Elias Jabbour;Nicholas J Short;Farhad Ravandi;Xuelin Huang

  • Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

    Naval Daver;Deborah Thomas;Farhad Ravandi;Jorge Cortes

  • Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

    Hagop Kantarjian;Farhad Ravandi;Nicholas J Short;Xuelin Huang

  • TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.

    Tapan M. Kadia;DM Preetesh Jain Md;Farhad Ravandi;Guillermo Garcia-Manero

  • Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

    Kate J. Newberry;Keyur Patel;Lucia Masarova;Rajyalakshmi Luthra

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Nitin Jain
Nitin Jain The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine but seeking flexible or alternative pathways, online healthcare degrees offer a range of accessible options. Pursuing a career in nursing is a popular choice, with nursing school online programs allowing students to balance studies with other commitments. These accredited programs provide a solid foundation in patient care and healthcare systems.

Existing registered nurses can advance their qualifications through rn to bsn online programs. These bridge programs are designed to enhance leadership skills and open doors to advanced nursing roles. For non-nurses aiming to enter the field, direct entry msn programs online offer an accelerated route to a master's degree and licensure.

Nurses interested in leadership, academia, or research can further their education with an online phd nursing degree. These programs enable working professionals to reach the highest levels of nursing practice, often without having to relocate or leave their jobs. Exploring these online pathways can lead to rewarding and impactful healthcare careers.

Best Scientists Citing Naval Daver

Trending Scientists

Recently Published Articles